GlassScriptPhysician profile
Mark J Schiller
NPI 1245445170
$5,676.00
in general payments reported to CMS, 2019-2025
24 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $151 · 2021: $660 · 2022: $932 · 2023: $1,110 · 2024: $994 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $880.92 | 2020-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $878.73 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $659.35 | 2021-2025 | Caplyta |
| Lundbeck LLC | $647.11 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Indivior INC. | $573.61 | 2019-2025 | Sublocade, Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $232.30 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $223.00 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $213.00 | 2024-2025 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $206.89 | 2020-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $204.16 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $187.31 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $147.65 | 2019-2022 | |
| Allergan, INC. | $135.50 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $129.10 | 2020-2025 | Fanapt, Hetlioz |
| Braeburn INC. | $76.06 | 2024-2025 | Brixadi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $58.90 | 2021-2023 | Ingrezza |
| Orexo US, INC. | $52.11 | 2019 | |
| Merck Sharp & Dohme LLC | $41.86 | 2022-2023 | Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $37.68 | 2022 | |
| Ironshore Pharmaceuticals INC. | $22.52 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.98 | 2025 | Qelbree |
| Alfasigma USA, INC. | $17.59 | 2022 | |
| Mdd US Operations, LLC | $15.72 | 2019 | |
| Pfizer INC. | $12.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.